Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

HER2 signaling can also promote cell survival and colonization at distant metastatic sites, establishing secondary tumors. HER2-positive tumors have different clinicopathological features and ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

The improvement in progression-free survival (PFS) was seen across a ... already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY ...

Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase ...

The Best of ASCO UAE Conference 2025, organised by SEHA, part of PureHealth Group, in collaboration with Tawam Hospital, ...

Dizal has completed subject enrolment for the randomised Phase III WU-KONG28 trial of oral sunvozertinib for treating NSCLC ...